Helicobacter pylori eradication for the prevention of gastric neoplasia

  • Protocol
  • Intervention

Authors


Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Primary outcome

To assess the proportion of individuals with gastric neoplasia in H. pylori positive subjects randomized to H. pylori eradication compared with placebo or no therapy.

Secondary outcomes

The following secondary outcomes will be assessed in H. pylori positive subjects randomized to H. pylori eradication compared with placebo or no therapy.

1. The proportion of individuals dying from gastric neoplasia.

2. The proportion of individuals with precancerous lesions (gastric atrophy, intestinal metaplasia and/or dysplasia) at baseline developing gastric neoplasia.

3. The proportion of individuals without precancerous lesions (gastric atrophy, intestinal metaplasia and/or dysplasia) at baseline developing gastric neoplasia.

4. The proportion of individuals with oesophageal adenocarcinoma.

5. The proportion of individuals with oesophageal squamous cell carcinoma.

6. The proportion of indivduals dying from any cause.

7. The proportion of adverse events associated with eradication therapy dichotomoused into present or absent.